StockData
AnaptysBio, Inc logo

AnaptysBio, Inc (ANAB) income statement

ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/30
$49.24+2.63 (+5.64%)

Close on Oct 19, 2026Market cap $2.28BP/E –Yield –

AnaptysBio, Inc income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
131.7%
Net margin
82.4%
Return on equity, FY2025
-24.5%

Financial strength

Current ratio
5.61
Debt to equity
–
Debt to assets
–
Cash to current liabilities
378.5%

Valuation

P/E ratio
–
Price to sales
9.59
Price to book
215.20
Dividend yield
–

See a number that looks wrong?